How Do I Decide to Treat Patients with Geographic Atrophy?

Related

• 

  Expert Panel: AI

  Mark S. Humayun, MD, PhD

  Devinder S Chauhan, MD FRCOphth FRANZCO

  Ursula M. Schmidt-Erfurth, MD

  Jennifer I. Lim, MD, FARVO, FASRS

  Royce WS Chen, MD

  Annual Meeting Talks

  2024

• 

  Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

  Jared S. Nielsen, MD, MBA

  Updates from the Field

  2022

• 

  Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs

  Ravi Parikh, MD MPH

  Annual Meeting Talks

  2023